Mia's Feed
Medical News & Research

Innovative Blood Test Promises Improved Early Detection of Alzheimer's in Underrepresented Groups

Innovative Blood Test Promises Improved Early Detection of Alzheimer's in Underrepresented Groups

Share this article

A new study highlights the potential of blood-based biomarkers to improve early Alzheimer’s detection among Hispanic and Latino populations, paving the way for accessible and scalable screening methods.

2 min read

A groundbreaking study conducted by researchers at the University of California, San Diego School of Medicine has revealed that blood-based biomarkers could significantly enhance early diagnosis of Alzheimer's disease and related dementias, especially among Hispanic and Latino populations. This research is a crucial step toward creating accessible, cost-effective, and less-invasive screening methods compared to traditional tools.

The study, examining over 5,700 Hispanic and Latino adults aged 50 to 86, identified correlations between self-reported cognitive decline and specific blood biomarkers. Notably, increased levels of nerve injury markers like NfL and brain inflammation markers such as GFAP were associated with participants’ perceptions of declining cognitive functions, including thinking, planning, and memory. Interestingly, concentrations of amyloid-beta proteins, commonly linked with Alzheimer’s in the brain, did not show a significant connection to subjective cognitive decline.

This research reflects the growing potential of blood tests in neurodegenerative disease detection, pointing toward earlier and more scalable diagnosis options. Dr. Freddie Márquez, a postdoctoral scholar involved in the study, emphasized that these biomarkers could serve as accessible tools particularly vital for underserved populations.

The findings also underscore the importance of diversity in Alzheimer's research. By focusing on Latino communities, the study sheds light on how social and biological factors influence disease risk and progression, making the results highly relevant for real-world applications.

Though promising, researchers caution that further studies are necessary to validate blood biomarkers for widespread clinical use. Current blood tests, like the FDA-approved Lumipulse G pTau217/Aβ42 test, are costly and limited to specialized environments. Nonetheless, the study’s insights pave the way for more inclusive, early detection strategies that could transform how Alzheimer's is diagnosed and managed in the future.

Source: https://medicalxpress.com/news/2025-09-blood-early-alzheimer-underrepresented-populations.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Precursor Cells to Bone Marrow Cancer Enter Dormant State to Prevent Disease Progression

New research reveals that precursor cells to bone marrow cancer can enter a dormant state, preventing disease progression and opening possibilities for early intervention strategies. Discover how cellular senescence acts as a natural defense mechanism against cancer.

AI Innovation Enhances Blood Test Accuracy for Faster Cancer Monitoring

A new AI-driven blood test method, Fragle, enables faster, affordable, and highly accurate cancer monitoring by analyzing DNA fragment sizes, promising improved detection of relapse and treatment response.

Artificial Intelligence Enhances Breast Cancer Detection in Screening Mammograms

Artificial intelligence shows promise in detecting one-third of interval breast cancers missed during screening, potentially reducing aggressive cancers diagnosed between exams.

Neuronal Cholesterol Transport Disrupted in Alzheimer's Disease Linked to APOE4 Gene Variant

A groundbreaking study links impaired cholesterol delivery to neurons with the APOE4 gene variant in Alzheimer's disease, opening new pathways for research and potential therapies.